These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9760448)

  • 1. Pharmacogenetics of CYP2C subfamily in a Japanese population.
    Ieiri I; Higuchi S
    J Toxicol Sci; 1998 Jul; 23 Suppl 2():129-31. PubMed ID: 9760448
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Genetic polymorphism of the CYP2C subfamily].
    Chiba K
    Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19.
    Yasumori T; Chen LS; Li QH; Ueda M; Tsuzuki T; Goldstein JA; Kato R; Yamazoe Y
    Biochem Pharmacol; 1999 Jun; 57(11):1297-303. PubMed ID: 10230773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.
    Veronese ME; Doecke CJ; Mackenzie PI; McManus ME; Miners JO; Rees DL; Gasser R; Meyer UA; Birkett DJ
    Biochem J; 1993 Jan; 289 ( Pt 2)(Pt 2):533-8. PubMed ID: 8424795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.
    Bajpai M; Roskos LK; Shen DD; Levy RH
    Drug Metab Dispos; 1996 Dec; 24(12):1401-3. PubMed ID: 8971149
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
    Lewis DF; Dickins M; Weaver RJ; Eddershaw PJ; Goldfarb PS; Tarbit MH
    Xenobiotica; 1998 Mar; 28(3):235-68. PubMed ID: 9574814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
    Borlak J; Thum T
    Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
    [No Abstract]   [Full Text] [Related]  

  • 12. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
    Miners J
    Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
    [No Abstract]   [Full Text] [Related]  

  • 13. [Status of pharmacogenomics and its future role in drug therapy].
    Cascorbi I
    Internist (Berl); 2002 Apr; 43(4):506-10. PubMed ID: 12053407
    [No Abstract]   [Full Text] [Related]  

  • 14. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.
    Thijssen HH; Verkooijen IW; Frank HL
    Pharmacogenetics; 2000 Nov; 10(8):757-60. PubMed ID: 11186138
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
    Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenytoin intoxication induced by fluvoxamine.
    Mamiya K; Kojima K; Yukawa E; Higuchi S; Ieiri I; Ninomiya H; Tashiro N
    Ther Drug Monit; 2001 Feb; 23(1):75-7. PubMed ID: 11206048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
    Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U
    Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.
    Kimura M; Ieiri I; Mamiya K; Urae A; Higuchi S
    Ther Drug Monit; 1998 Jun; 20(3):243-7. PubMed ID: 9631918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian.
    Inoue K; Yamazaki H; Shimada T
    Xenobiotica; 1998 Apr; 28(4):403-11. PubMed ID: 9604303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genetic polymorphisms of drug metabolizing enzymes].
    Fujieda M; Yamazaki H; Kamataki T
    Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.